Weyer Christian 4
4 · INTERCEPT PHARMACEUTICALS, INC. · Filed Jan 26, 2021
Insider Transaction Report
Form 4
Weyer Christian
EVP Research and Development
Transactions
- Award
Option to Purchase Common Stock
2021-01-22+19,700→ 19,700 totalExercise: $29.46Exp: 2031-01-22→ Common Stock (19,700 underlying) - Award
Common Stock
2021-01-22+12,600→ 27,744 total
Footnotes (2)
- [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2021.
- [F2]The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2021.